Does Rallies show 13F holders for XERS?

Yes. Rallies tracks hedge fund and 13F ownership data for XERS, including fund names, share counts, latest tracked quarter, and position changes when available.

Is XERS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for XERS. It does not provide personalized investment advice.

XERS (Xeris Biopharma Holdings, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Xeris Biopharma Holdings, Inc. Common Stock (XERS) is a publicly traded Healthcare sector company. As of May 21, 2026, XERS trades at $6.21 with a market cap of $1.04B and a P/E ratio of 88.21. XERS moved +5.07% today. Year to date, XERS is -12.13%; over the trailing twelve months it is +22.64%. Its 52-week range spans $2.69 to $10.08. Analyst consensus is strong buy with an average price target of $12.25. Rallies surfaces XERS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns XERS stock?

Hedge funds tracked by Rallies that own XERS include Centerbook Partners, Redmile Group, Fairfax Financial, Polen Capital, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Xeris Biopharma Holdings, Inc. Common Stock.

XERS Key Metrics

Key financial metrics for XERS
Metric	Value
Price	$6.21
Market Cap	$1.04B
P/E Ratio	88.21
EPS	$0.07
Dividend Yield	0.00%
52-Week High	$10.08
52-Week Low	$2.69
Volume	2.61K
Avg Volume	0
Revenue (TTM)	$314.85M
Net Income	$12.01M
Gross Margin	0.00%

Top Hedge Funds Holding XERS

Centerbook Partners holds 1.25M shares of XERS, changed -10.27% as of Mar 31, 2026.
Redmile Group holds 451.10K shares of XERS, changed +0.00% as of Sep 30, 2025.
Fairfax Financial holds 139.69K shares of XERS, changed -18.28% as of Dec 31, 2024.
Polen Capital holds 133.42K shares of XERS, changed +0.17% as of Dec 31, 2025.
Panagora Asset holds 104.74K shares of XERS, changed -28.02% as of Mar 31, 2026.

Latest XERS News

Xeris Biopharma Tops Q4 EPS Estimates, Reports $85.8M Revenue — Mar 2, 2026
Xeris Biopharma Files Patent Lawsuit, Shares Drop 10.8% on Recorlev Threat — Feb 27, 2026

Recent XERS Insider Trades

Hecht Beth sold 16.67K (~$103.81K) on May 1, 2026.
Hecht Beth sold 16.67K (~$99.86K) on Apr 1, 2026.
Brady James Aloysius sold 10.83K (~$60.04K) on Mar 30, 2026.

XERS Analyst Consensus

4 analysts cover XERS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.25.

Common questions about XERS

Who owns XERS stock?: Hedge funds tracked by Rallies that own XERS include Centerbook Partners, Redmile Group, Fairfax Financial, Polen Capital, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Xeris Biopharma Holdings, Inc. Common Stock.
Does Rallies show 13F holders for XERS?: Yes. Rallies tracks hedge fund and 13F ownership data for XERS, including fund names, share counts, latest tracked quarter, and position changes when available.
Is XERS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for XERS. It does not provide personalized investment advice.